Neural Interfaces Will Hit a Blood-Brain Barrier Before a Bandwidth Barrier — Chronic Neuroinflammation Is the Real Bottleneck

Neuralink can record from 1024 electrodes. The engineering is impressive. But within months of implantation, glial scarring encapsulates the electrode array, increasing impedance and degrading signal quality. This isn't a solved problem — it's the fundamental challenge that determines whether BCIs become clinical tools or remain laboratory demonstrations.
The foreign body response to implanted electrodes involves activated microglia, reactive astrocytes, and eventual fibrotic encapsulation. Signal-to-noise ratio degrades 50-80% within the first year for penetrating arrays (Barrese et al., 2013, J Neural Engineering).
Hypothesis: The maximum useful lifespan of current penetrating neural interfaces is 5-7 years, after which glial scarring will reduce channel count below clinical utility regardless of electrode material or coating. Overcoming this requires either: (a) electrode-free recording (e.g., optogenetics, magnetogenetics) or (b) active immunomodulation at the implant site (local IL-10 delivery, microglial CSF1R inhibition).
Prediction: Neuralink's N1 implant will show >40% channel degradation by year 3 in human subjects, necessitating reimplantation or supplementary recording strategies.